Revenue grew 6.6% year-over-year to IDR 1.36T in 3M26, with net income up 3.8% and EBITDA margin at 37.6%. Private revenue share rose to 89%, and expansion plans include seven new hospitals and advanced oncology services.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.